Processa Pharmaceuticals (PCSA) Accounts Payables (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Accounts Payables came in at $840370.0 in Q1 2026, up 52.09% YoY from $552560.0 in Q1 2025, and down 20.48% on a QoQ basis from $1.1 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Accounts Payables (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Accounts Payables data on file, last reported at $840370.0 in Q1 2026.
- Quarterly Accounts Payables rose 52.09% year-over-year to $840370.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $840370.0 (up 52.09% YoY) and the FY2025 annual result came in at $1.1 million, up 19.97% from the prior year.
- Accounts Payables fell to $840370.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.1 million in Q4 2025 to a low of $239022.0 in Q2 2023.
- A 5-year average of $575303.1 and a median of $552560.0 in 2025 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 63.12% — and 2024, when it jumped 298.74%.
- Tracing PCSA's Accounts Payables over 5 years: stood at $327548.0 in 2022, then slipped by 4.86% to $311617.0 in 2023, then jumped by 182.68% to $880880.0 in 2024, then gained by 19.97% to $1.1 million in 2025, then slipped by 20.48% to $840370.0 in 2026.
- The last three Accounts Payables figures came in at $840370.0 (Q1 2026), $1.1 million (Q4 2025), and $727172.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | Processa Pharmaceuticals | 5.78 Mn | 5.78 Mn | - | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 840,370.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 727,172.00 |
| Jun 30, 2025 | 785,754.00 |
| Mar 31, 2025 | 552,560.00 |
| Dec 31, 2024 | 880,880.00 |
| Sep 30, 2024 | 711,710.00 |
| Jun 30, 2024 | 953,086.00 |
| Mar 31, 2024 | 455,368.00 |
| Dec 31, 2023 | 311,617.00 |
| Sep 30, 2023 | 346,299.00 |
| Jun 30, 2023 | 239,022.00 |
| Mar 31, 2023 | 316,709.00 |
| Dec 31, 2022 | 327,548.00 |
| Sep 30, 2022 | 311,066.00 |
| Jun 30, 2022 | 648,104.00 |
| Mar 31, 2022 | 316,092.00 |
| Dec 31, 2021 | 218,905.00 |
| Sep 30, 2021 | 354,977.00 |
| Jun 30, 2021 | 287,878.00 |